April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
SCY-641 - A Water-Soluble Cyclophilin Inhibitor for the Treatment of Dry Eye Disease
Author Affiliations & Notes
  • Michael Peel
    Chemistry,
    Scynexis, Inc, Durham, North Carolina
  • Andrew Scribner
    Chemistry,
    Scynexis, Inc, Durham, North Carolina
  • Keqiang Li
    Chemistry,
    Scynexis, Inc, Durham, North Carolina
  • Bernard Scorneaux
    Biochemistry,
    Scynexis, Inc, Durham, North Carolina
  • Sarah Mosier
    Biochemistry,
    Scynexis, Inc, Durham, North Carolina
  • Karen Polowy
    Chemistry,
    Scynexis, Inc, Durham, North Carolina
  • Weslyn Ward
    DMPK,
    Scynexis, Inc, Durham, North Carolina
  • Eric Gaukel
    DMPK,
    Scynexis, Inc, Durham, North Carolina
  • Brian Gilger
    Veterinary Medicine, NCSU, Raleigh, North Carolina
  • Footnotes
    Commercial Relationships  Michael Peel, SCYNEXIS INC (E); Andrew Scribner, SCYNEXIS INC (E); Keqiang Li, SCYNEXIS INC (E); Bernard Scorneaux, SCYNEXIS INC (E); Sarah Mosier, SCYNEXIS INC (E); Karen Polowy, SCYNEXIS INC (E); Weslyn Ward, SCYNEXIS INC (E); Eric Gaukel, SCYNEXIS INC (E); Brian Gilger, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4324. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Peel, Andrew Scribner, Keqiang Li, Bernard Scorneaux, Sarah Mosier, Karen Polowy, Weslyn Ward, Eric Gaukel, Brian Gilger; SCY-641 - A Water-Soluble Cyclophilin Inhibitor for the Treatment of Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4324.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To identify a water soluble cyclosporine derivative with good immunomodulatory properties and ocular distribution profile consistent with treating dry eye disease.

Methods: : New semi-synthetic derivatives of cyclosporine A were prepared and tested for immunosuppressive potential (inhibition of IL-2 from stimulated Jurkat T-cells) and anti-cytokine activity (inhibition of TNF, IL-1 from corneal epithelial cells). The solubility of new compounds in water, and water/excipient mixtures, was measured by shake-flask methods with HPLC analysis. The ocular distribution of lead compounds was determined by topical administration to rabbits followed by measurement of corneal and conjunctival tissue concentrations.

Results: : SCY-641 was identified as a potent inhibitor of cytokine production by stimulated corneal epithelial cells (TNF, IL-1 IC50 0.6, 11 uM) and T-cells (IL-2 IC50 0.04 uM), and to be immunosuppressive in a mixed lymphocyte proliferation assay (EC50 0.2 uM) . The solubility of SCY-641 in water, PEG/water and carboxymethylcellulose/water (0.17, 0.24, and 0.3 mg/mL) was 10-30 fold higher than corresponding values for cyclosporine A. A clear solution of SCY-641 (0.3 mg/mL, 0.03%) in a CMC/water vehicle, autoclaved to achieve sterility, was found to be stable over several months. Topical administration of a 0.03% SCY-641 solution (0.05 mL, q15minX4) to rabbit eyes was well tolerated (slit lamp microscopy, Shaddock-McDonald scoring) and resulted in corneal and conjunctival concentrations (2000 and 2100 ng/g tissue respectively) above the anticipated therapeutic range.

Conclusions: : SCY-641 is a new cyclosporine derivative with good immunosuppressive, and anti-cytokine, activity and notably improved aqueous solubility. SCY-641 is readily taken into rabbit corneal and conjunctival tissue following topical application and warrents further evaluation as an alternative treatment for Dry Eye disease.

Keywords: cyclosporine • cornea: tears/tear film/dry eye • aqueous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×